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Abstract
Rheumatoid arthritis represents an excellent model in which to gain insights into the local
and systemic effects of joint inflammation on skeletal tissues. Three forms of bone disease
have been described in rheumatoid arthritis. These include: focal bone loss affecting the
immediate subchondral bone and bone at the joint margins; periarticular osteopenia
adjacent to inflamed joints; and generalized osteoporosis involving the axial and
appendicular skeleton. Although these three forms of bone loss have several features in
common, careful histomorphometric and histopathological analysis of bone tissues from
different skeletal sites, as well as the use of urinary and serum biochemical markers of bone
remodeling, provide compelling evidence that different mechanisms are involved in their
pathogenesis. An understanding of these distinct pathological forms of bone loss has
relevance not only with respect to gaining insights into the different pathological
mechanisms, but also for developing specific and effective strategies for preventing the
different forms of bone loss in rheumatoid arthritis.
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Introduction
Inflammatory joint diseases such as rheumatoid arthritis
(RA), the seronegative spondyloarthropathies, and juve-
nile arthritis comprise a heterogeneous group of disor-
ders that share a propensity to destroy the extracellular
matrices of joint cartilage and bone. To dissect the
pathophysiological mechanisms that are responsible for
the loss of cartilage and bone, it is necessary to deter-
mine whether the destruction of these matrices is medi-
ated by the same cell types that remodel these tissues
under physiological conditions. This question can be
addressed in part by careful histopathological examina-
tion and characterization of the diseased joint structures
using techniques that identify the phenotype of cell pop-
ulations within the bone and cartilage matrices. In addi-
tion, it is essential to know whether the loss of bone and
cartilage is the result of impaired synthesis of the extra-
cellular matrix components or is related to an enhanced
rate of their breakdown. The development of biochemical
assays for quantitating bone and cartilage remodeling
indices (formation and degradation) and the availability
of improved imaging techniques for assessing bone and
cartilage loss have provided new insights into these
pathological events. This review focuses on the mecha-
nisms of bone loss in RA, and explores the diagnostic
and therapeutic implications of these findings.Arthritis Research    Vol 2 No 1 Goldring and Gravallese
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Rheumatoid arthritis as a model of
inflammatory arthritis
Among the inflammatory arthritides, RA represents an
excellent model for gaining insights into the local and sys-
temic effects of joint inflammation on skeletal tissues. Three
forms of bone disease have been described in RA. These
include: focal bone loss affecting the immediate subchon-
dral bone and bone at the joint margins; periarticular
osteopenia adjacent to inflamed joints; and generalized
osteoporosis involving the axial and appendicular skeleton
[1–3]. Although these three forms of bone loss have
several features in common, careful histomorphometric and
histopathological analysis of bone tissues from different
skeletal sites provide compelling evidence that different
mechanisms are involved in their pathogenesis.
A general understanding of the cellular and biochemical
events associated with skeletal remodeling is essential for
defining the pathophysiology of bone loss in RA. Through-
out life the skeleton is in a dynamic state of remodeling,
during which discrete packets of bone (termed bone
remodeling units or basic multicellular units by Frost [4]
and Parfitt [5]) are resorbed and new bone formed to
replace the resorbed matrix. In trabecular bone each
remodeling cycle (estimated to be between 3 and 4
months) is initiated at a previously quiescent bone surface
by the recruitment of osteoclast precursors, which are
cells of monocyte/macrophage lineage. These precursor
cells subsequently differentiate into active bone resorbing
osteoclasts [6]. After cessation of the resorption cycle the
bone surface is lined by osteoblasts that synthesize new
bone matrix. This unmineralized bone matrix, or osteoid,
subsequently undergoes mineralization. Under physiologi-
cal conditions the activity of the osteoclasts and
osteoblasts is tightly controlled, such that with each
remodeling cycle the amount of bone that is removed is
exactly replaced. This process provides a mechanism for
repair of local microdamage to the skeleton and permits
adaptation to changing biomechanical factors.
Although the focal bone erosions and juxta-articular and
systemic bone loss in RA involve different regions of the
skeleton, implicit in each of these patterns of bone loss is
the presence of a disequilibrium in the absolute rate of
bone resorption and formation that is independent of the
specific cellular and pathological events. An understand-
ing of these distinct pathological forms of bone loss has
relevance not only with respect to gaining insights into the
different pathological mechanisms, but also for developing
specific and effective strategies for preventing these forms
of bone loss in RA.
Focal bone loss in rheumatoid arthritis
Insights into the pathogenesis of the progressive focal
bone erosions and subchondral osteolysis that character-
izes RA have been provided by histopathological analysis
of the bone–pannus junction and subchondral bone
marrow [7–11]. These studies demonstrated the pres-
ence in resorption lacunae of multinucleated cells that
express the entire repertoire of mature osteoclasts,
including the presence of tartrate-resistant acid phos-
phatase and cathepsin K activity and the expression of
calcitonin receptor mRNA. These observations provide
good evidence that the focal bone resorption at these
sites is mediated by cells with phenotypic features and
functional activities of authentic osteoclasts. These con-
clusions are further supported by work in animal models
of inflammatory arthritis [12,13].
Additional studies indicate that rheumatoid synovial
tissues are enriched with cells of the monocyte/
macrophage lineage that, with appropriate stimuli, can
be induced to differentiate into preosteclasts and ulti-
mately into fully functional osteoclasts [14–16]. In addi-
tion, several studies have shown that synovial tissues
are a rich source of a number of cytokines and inflam-
matory mediators that possess the capacity to induce
the recruitment, differentiation, and activation of osteo-
clasts. These include interleukin (IL)-1a and IL-1b,
tumor necrosis factor (TNF)-a, macrophage colony-stim-
ulating factor, IL-6, IL-11, parathyroid hormone-related
peptide, and the newly described T-cell derived
cytokine IL-17 [17–23]. Of interest, many of these
cytokines, especially IL-6, IL-11, and macrophage
colony-stimulating factor, function under physiological
conditions of bone remodeling to induce osteoclast dif-
ferentiation. The local production of these factors by the
inflamed synovium, as well as the production of proin-
flammatory factors, including IL-1a and IL-1b, TNF-a, IL-
17 and parathyroid hormone-related peptide, by the
inflamed RA synovium could be responsible for the
recruitment of osteoclast precursors to the bone
microenvironment where they are induced to differenti-
ate to activated osteoclasts.
Recent studies [24] have identified an additional potent
regulator of osteoclast differentiation: osteoclast differenti-
ation factor (ODF). Under conditions of physiological bone
remodeling, interaction of ODF with its receptor, receptor
activator of nuclear factor-kB, on the surface of osteoclast
precursors leads to differentiation of these cells to osteo-
clasts. Of interest with respect to the T-cell infiltrate within
RA synovium, ODF is identical to the TNF-related activa-
tion-induced cytokine that is expressed on antigen-stimu-
lated T cells [25]. Our laboratory and others have recently
reported the expression of ODF in T cells and fibroblast-
like cells in rheumatoid synovium [26–28]. That ODF plays
a role in the pathological bone resorption in inflammatory
arthritis is supported by the studies of Kong et al [28],
who demonstrated that treatment with osteoprotegerin,
the soluble receptor for ODF, prevents bone erosions in a
model of adjuvant arthritis.35
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The demonstration that the focal bone erosions in RA are
generated, at least in part, by cells expressing an osteo-
clast phenotype suggests that agents that affect osteo-
clast recruitment, differentiation or activity would be
rational targets for preventing this form of bone loss. Only
limited data are available regarding this topic and, thus far,
although there are data that indicate that agents that block
osteoclast-mediated bone resorption can prevent sys-
temic bone loss, there are no definitive findings from trials
in humans that demonstrate the efficacy of these therapies
in blocking focal bone erosions in RA [29–35]. There are
data in animal models of inflammatory arthritis, however,
that indicate that inhibition of osteoclast-mediated bone
resorption with bisphosphonates may have efficacy in
blocking focal bone erosions [36,37]. Clearly, further
studies are needed to explore fully the potential beneficial
effects of agents that block osteoclast-mediated bone
resorption in this form of bone disease.
The absence of more definitive data regarding the utility of
therapeutic intervention in the prevention of focal bone
disease in RA is due in part to the difficulty of assessing the
progression of bone erosions, because standard radi-
ographs lack sufficient sensitivity to detect and quantitate the
progression of bone lesions. Recent advances in magnetic
resonance imaging techniques that employ gadolium-diethyl-
enetriaminepenta-acetic acid and T2-pulse sequences to
suppress fat signals allow for the identification of early focal
bone loss. These techniques hold significant promise for the
evaluation of treatment interventions to block focal bone ero-
sions [11]. Further studies with these technologies, as well
as other refinements in imaging modalities, should enhance
the feasibility of these types of investigation.
Periarticular osteopenia
The second form of bone loss observed in patients with
RA is the presence of periarticular osteopenia adjacent to
inflamed joints. Histological examination of this bone
tissue reveals the presence in the marrow space of local
aggregates of inflammatory cells, including macrophages
and lymphocytes. There is an increase in the surface of
bone covered by osteoid, as well as an increase in resorp-
tion surfaces, which are often populated by osteoclasts.
These findings are consistent with an increase in bone
remodeling with a net increase in bone resorption [38,39].
Although decreased joint motion and immobilization in
response to the adjacent synovial inflammation probably
contribute to the juxta-articular bone loss, these changes
could also reflect local responses within the marrow
space to proinflammatory products released from the adja-
cent RA synovial tissues. Although osteoclasts are the
likely cell type responsible for the bone resorption in this
form of bone loss, the absence of direct synovial interac-
tion with the bone surfaces indicates that different cellular
interactions are involved in the recuritment and activation
of the bone resorbing cells.
Axial and appendicular osteopenia
The third form of bone loss associated with RA is general-
ized axial and appendicular osteopenia, which has been
detected using multiple different techniques for assessing
skeletal mass [40–43]. Importantly, there is compelling evi-
dence that the reduction in bone mass is associated with an
increased risk of hip and vertebral fracture [41,44–46].
Although there has been speculation that cytokines such as
IL-1a or IL-1b, TNF-a and IL-6 (released into the circulation
from inflamed joints) contribute to systemic bone loss by
acting in an endocrine manner to affect bone remodeling
adversely, there are no direct data to support this hypothesis
[2,3]. In part, the difficulty in defining the specific patho-
genetic mechanisms responsible for this pattern of bone loss
in RA can be attributed to the presence of multiple con-
founding factors in this patient population. These include the
influence of patient sex, age, mobility, disease activity and
duration, and the concomitant use of immunosuppressive
therapies and/or glucocorticoids, all of which have indepen-
dent effects on bone metabolism. Among these variables,
disease activity and duration appear to be of particular
importance with respect to the risk for reduced bone mass
[40,47]. Of importance, a significant amount of generalized
skeletal bone appear to be lost early in RA and the magni-
tude of this loss is associated with the level of disease activ-
ity [40,45,48,49]. These findings have obvious implications
with respect to early interventions to prevent bone loss.
Several different approaches have been used to define the
mechanisms responsible for the generalized bone loss
associated with RA. Histomorphometric analysis of bone
biopsies [50,51] indicate that, in the absence of corticos-
teroid use, the generalized bone loss in RA is related to a
decrease in bone formation rather than to an increase in
bone resorption. In contrast, analysis of biochemical
markers of bone turnover using the pattern of urinary excre-
tion of collagen pyridinoline and deoxypyridinoline
crosslinks to quantitate bone resorption [39,40,52–55]
indicates that systemic bone loss in RA is related primarily
to an increase in bone resorption rates. Furthermore, excre-
tion of both urinary markers was significantly increased in
patients with active disease who lost bone quickly. The dis-
crepancy between the findings from histomorphometric
and biochemical markers studies could in part be related to
the stage of the disease at the time of the analyses (eg
early versus late), as well as to the level of disease activity.
The importance of disease activity on bone remodeling
indices was illustrated by the studies of Gough et al [39]
who showed that the levels of the urinary markers of bone
resorption were highly correlated with C-reactive protein.
Bone formation indices, as assessed by measurement of
serum alkaline phosphatase and procollagen I carboxyter-
minal propeptide levels, were not significantly suppressed,
suggesting that suppression of bone formation was mar-
ginal and not a dominant factor contributing to the acceler-
ated bone loss in patients with active disease.Therapeutic approaches to prevent
generalized bone loss in rheumatoid arthritis
Increasing awareness of the morbidity associated with
generalized bone loss in patients with RA has lead to the
initiation of several clinical trials designed to prevent sys-
temic bone loss. Most of the studies have focused on the
effects of antiresorptive therapies on generalized bone
loss. Results of these investigations indicate that agents
including estrogens, calcitonin, or bisphosphonates may
have clinical efficacy in preventing systemic bone loss. For
example, in prospective studies [32–35], estrogens were
shown to improve bone density modestly in post-
menopausal women with RA. Similarly, calcitonin in short-
term studies [30,31] has been shown to increase
trabecular bone volume and bone mineral density as
assessed by forearm densitometry. In a prospective con-
trolled 3-year trial, Egglemeiger et al [29] showed that
treatment with the bisphosphonate pamidronate resulted
in a significant increase in bone mineral density in the
lumbar spine and hip compared with a placebo group.
This was accompanied by a reduction in urinary hydrox-
yproline excretion in the pamidronate-treated group, which
is consistent with suppression of bone resorption. Of
interest, those investigators detected no change in the
progression of focal bone erosions in their treated
patients, suggesting that the bisphosphonate failed to
prevent this form of bone loss. Whether this lack of effi-
cacy in preventing focal bone erosions was related to drug
dosage or to other factors related to disease activity or
concomitant therapies will require further investigation.
Treatment strategies to increase bone mass
To date there have been no studies in patients with RA
that have explored treatment modalities specifically
designed to increase bone formation rates. In part, this
reflects the absence of agents that can directly increase
osteoblastic activity. Recently Lane et al [56] used a
regimen of intermittent low-dose parathyroid hormone to
treat corticosteroid-induced osteoporosis. These findings
indicate that this strategy, or a related approach using, for
example, other cytokines or growth factors with the capac-
ity to increase bone formation, may hold promise for the
treatment of generalized bone loss in patients with RA.
Critical to the successful evaluation of the efficacy of
agents designed to prevent the various forms of bone loss
in patients with RA will be the development of cost-effec-
tive, sensitive, and specific noninvasive techniques for
monitoring the effects of these treatments on the bone
disease. It is also essential that these approaches be able
to identify the effects of these treatments on the specific
patterns of bone loss. The overall goal of treatment of RA
is the suppression or eradication of the primary immune
disorder that is responsible for the synovial lesion. It is
nevertheless possible to develop treatment strategies that
can help protect the skeletal tissues from the ravages of
the inflammatory process, even in the absence of a defini-
tive disease cure.
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